|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.3775 EUR | +0.94% |
|
+2.58% | +26.68% |
| 06-23 | Nicox Bags EUR6 Million Shareholder Loan | MT |
| 06-23 | Nicox Secures Backing From a Shareholder and Financial Partner |  |
| Market Cap | 33.27M 38.01M 30.71M 28.65M 53.98M 3.59B 54.94M 368M 143M 1.77B 143M 140M 6.18B | P/E 2026 * |
37.8x | P/E 2027 * | 3.15x |
|---|---|---|---|---|---|
| Enterprise Value | 33.27M 38.01M 30.71M 28.65M 53.98M 3.59B 54.94M 368M 143M 1.77B 143M 140M 6.18B | EV / Sales 2026 * |
3.33x | EV / Sales 2027 * | 1.66x |
| Free-Float |
99.65% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | +0.94% | ||
| 1 week | +2.58% | ||
| 1 month | -1.69% | ||
| 3 months | -4.19% | ||
| 6 months | +26.68% | ||
| Current year | +26.68% |
| 1 week | 0.36 |  | 0.38 |
| 1 month | 0.34 | | 0.42 |
| Current year | 0.29 | | 0.57 |
| 1 year | 0.22 | | 0.65 |
| 3 years | 0.14 | | 0.65 |
| 5 years | 0.14 | | 3.9 |
| 10 years | 0.14 | | 13.68 |
| Manager | Title | Age | Since |
|---|---|---|---|
Gavin Spencer
CEO | Chief Executive Officer | 55 | 28/02/2024 |
Sandrine Gestin
DFI | Director of Finance/CFO | 58 | 01/01/2015 |
Doug Hubatsch
CTO | Chief Tech/Sci/R&D Officer | - | 13/12/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Gavin Spencer
BRD | Director/Board Member | 55 | 08/04/2024 |
Damian Marron
CHM | Chairman | 64 | 16/07/2024 |
Marc Bozec
BRD | Director/Board Member | - | 16/07/2024 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 29/01/22 | Free | Chief Executive Officer | 15,000 | 0.0348% | ||
| 16/02/21 | Fiscal year | Chief Executive Officer | 10,000 | 0.0270% | ||
| 01/02/20 | Free | Chief Executive Officer | 10,000 | 0.0300% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.94% | +2.58% | +62.72% | -23.43% | 37.64M | |
| -0.68% | +7.44% | +62.33% | +11.36% | 320B | |
| +0.31% | +8.78% | +33.50% | -3.10% | 72.69B | |
| +1.41% | +12.42% | +50.46% | +116.99% | 9.15B | |
| -0.97% | +0.35% | +5.19% | -4.51% | 8.33B | |
| -4.94% | +5.35% | -5.87% | +7.05% | 4.62B | |
| +0.98% | +11.52% | +12.29% | +35.48% | 3.99B | |
| -4.88% | +0.57% | -32.63% | +22.04% | 3.57B | |
| -0.62% | +4.56% | +47.56% | +54.72% | 2.72B | |
| -1.71% | +8.00% | +14.12% | -24.15% | 2.18B | |
| Average | -1.01% | +5.25% | +24.97% | +19.25% | 42.68B | |
| Weighted average by Cap. | -0.54% | +10.92% | +53.71% | +11.21% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 10M 11.42M 9.23M 8.61M 16.22M 1.08B 16.51M 111M 42.99M 533M 42.92M 41.96M 1.86B | 20M 22.85M 18.46M 17.22M 32.45M 2.16B 33.03M 221M 85.98M 1.07B 85.84M 83.93M 3.71B |
| Net income | 1M 1.14M 923K 861K 1.62M 108M 1.65M 11.07M 4.3M 53.3M 4.29M 4.2M 186M | 11M 12.57M 10.15M 9.47M 17.85M 1.19B 18.17M 122M 47.29M 586M 47.21M 46.16M 2.04B |
| Net Debt | - | - |
Employees
10
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/06/26 | €0.3775 | +0.94% | 173,088 |
| 29/06/26 | €0.3740 | +1.63% | 140,978 |
| 26/06/26 | €0.3680 | +0.55% | 84,940 |
| 25/06/26 | €0.3660 | -2.66% | 167,084 |
| 24/06/26 | €0.3760 | +2.17% | 96,878 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.3775EUR
Average target price
1.000EUR
Spread / Average Target
+164.90%
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ALCOX Stock
Select your edition
All financial news and data tailored to specific country editions
